Structure-based design and synthesis of Nω-nitro-L-arginine- containing peptidomimetics as selective inhibitors of neuronal nitric oxide synthase. Displacement of the heme structural water

Journal of Medicinal Chemistry

Volumn 50, Issue 9, 2007, Pages 2089-2099

  Seo, Jiwon ^a   Igarashi, Jotato ^c   Li, Huiying ^c   Martásek, Pavel ^b   Roman, Linda J ^b   Poulos, Thomas L ^c   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 N [N(G) NITROARGINYL] 4 AMINOPROLINAMIDE; ARGININE DERIVATIVE; HEME; N [4 AMINO 5 [(2 AMINOETHYLAMINO)PENTYL] N' NITROGUANIDINE; N(G) NITROARGININE; N(G) NITROARGININE DERIVATIVE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; WATER;

ARTICLE; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; HYDROGEN BOND; INHIBITION KINETICS; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

BIOMIMETICS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HEME; HYDROGEN BONDING; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NITRIC OXIDE SYNTHASE TYPE I; NITROARGININE; PEPTIDES; PROTEIN ISOFORMS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; WATER;

EID: 34247559015     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061305c     Document Type: Article

References (74)

1. (a) Kerwin, J. F., Jr.; Lancaster, J. R., Jr. Nitric Oxide; a New Paradigm for Second Messengers. Med. Res. Rev. 1994, 14, 23-74.
2. (b) Stuehr, D. J. Enzymes of the L-Arginine to Nitric Oxide Pathway. J. Nutr. 2004, 134 (10, Suppl.), 2748S-2751S.
3. (a) Waldman, S. A.; Murad, F. Cyclic GMP Synthesis and Function. Pharmacol. Rev. 1987, 39, 163-196.
4. (b) Hobbs, A. J. Soluble Guanylate Cyclase: the Forgotten Sibling. Trends. Pharmacol. Sci. 1997, 18, 484-491.
5. (c) Denninger, J. W.; Marietta, M. A. Guanylate Cyclase and the NO/cGMP Signaling Pathway. Biochem. Biophys. Acta 1999, 1411, 334-350.
6. (a) Moncada, S.; Palmer, R. M. J.; Higgs, E. A. Nitric Oxide: Physiology, Pathophysiology, and Pharmacology. Pharmacol. Rev. 1991, 43, 109-142.
7. (b) Moncada, S.; Higgs, E. A. Molecular Mechanisms and Therapeutic Strategies Related to Nitric Oxide. FASEB J. 1995, 9, 1319-1330.
8. (a) Hardy, P.; Abran, D.; Hou, X.; Lahaie, I.; Peri, K. G.; Asselin, P.; Varma, D. R.; Chemtob, S. A Major Role for Prostacyclin in Nitric Oxide-Induced Ocular Vasorelaxation in the Piglet. Circ. Res. 1998, 83, 721-729.
9. (b) Wink, D. A.; Miranda, K. M.; Espey, M. G.; Mitchell, J. B.; Grisham, M. B.; Fukuto, J.; Feelish, M. The Chemical Biology of Nitric Oxide. Balancing Nitric Oxide with Oxidative and Nitrosative Stress. Handb. Exp. Pharmacol. 2000, 143, 7-29.
10. Moncada, S.; Higgs, A.; Furchgott, XIV, R. International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol. Rev. 1997, 49, 137-142.
11. Schmidt, H. H. H. W.; Walter, U. NO at Work. Cell 1994, 78, 919-925.
12. Forstermann, U.; Pollock, J. S.; Schmidt, H. H. H. W.; Heller, M.; Murad, F. Calmodulin Dependent Endothelium-Derived Relaxing Factor/Nitric Oxide Synthase Activity is Present in the Paniculate and Cytosolic Fractions of Bovine Aortic Endothelial Cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1788-1792.
13. MacMicking, J.; Xie, Q. W.; Nathan, C. Nitric Oxide and Macrophage Function. Annu. Rev. Immunol. 1997, 15, 323-350.
14. Roman, L. J.; Martásek, P.; Masters, B. S. S. Intrinsic and Extrinsic Modulation of Nitric Oxide Synthase Activity. Chem. Rev. 2002, 102, 1179-1189.
15. (a) Kleinert, H.; Pautz, A.; Linker, K.; Schwarz, P. M. Regulation of the Expression of Inducible Nitric Oxide Synthase. Eur. J. Pharmacol. 2004, 500, 255-266.
16. (b) Wu, C.; Thiemermann, C. Biological Control and Inhibition of Induction of Nitric Oxide Synthase. Methods Enzymol. 1996, 268, 408-420.
17. (a) Knowles, R. G.; Moncada, S. Nitric Oxide Synthases in Mammals. Biochem. J. 1994, 298, 249-258.
18. (b) Masters, B. S.; McMillan, K.; Sheta, E. A.; Nishimura, J. S.; Roman, L. J.; Martásek, P. Neuronal Nitric Oxide Synthase, a Modular Enzyme Formed by Convergent Evolution: Structure Studies of a Cystein Thiolate-Liganded Heme Protein that Hydroxylates L-Arginine to Produce NO as a Cellular Signal. FASEB J. 1996, 10, 552-558.
19. (a) Raman, C. S.; Martásek, P.; Masters, B. S. S. The Porphyrin Handbook; Academic Press: New York, 2000; pp 293-339.
20. (b) Raman, C. S.; Li, H.; Martásek, P.; Král, V.; Masters, B. S. S.; Poulos, T. L. Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase: a Paradigm for Pterin Function Involving a Novel Metal Center. Cell 1998, 95, 939-950.
21. (c) Fishmann, T. O.; Hruza, A.; Niu, X. D.; Fossetta, J. D.; Junn, C. A.; Dolphin, E.; Prongay, A. J.; Reichert, P.; Lundell, D. J.; Narula, S. K.; Weber, P. C. Structural Characterization of Nitric Oxide Synthase Isoforms Reveals Striking Active-Site Conservation. Nat. Struct. Biol. 1999, 6, 233-242.
22. Siddhanta, U.; Presta, A.; Fan, B.; Wolan, D.; Rousseau, D. L.; Stuehr, D. J. Domain Swapping in Inducible Nitric Oxide Synthases. Electron Transfer Occurs Between Flavin and Heme Groups Located on Adjacent Subunits in the Dimer. J. Biol. Chem. 1998, 273, 18950-18958.
23. (a) Vallance, P.; Leiper, J. Blocking NO Synthesis: How, Where and Why. Nat. Rev. Drug Discovery 2002, 1, 939-950.
24. (b) Grunewald, T.; Beal, M. F. NOS Knockouts and Neuroprotection. Nat. Med. 1999, 5, 1354-1355.
25. Uehara, T.; Nakamura, T.; Yao, D.; Shi, Z.; Gu, Z.; Ma, Y.; Masliah, E.; Nomura, Y.; Lipton, S. A. S-Nitrosylated Protein-disulphide Isomerase Links Protein Misfolding to Neurodegeneration. Nature 2006, 441, 513-517.
26. (a) Erdal, E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Ji, H.; Silverman, R. B. Selective Neuronal Nitric Oxide Synthase Inhibitors. Curr. Top. Med. Chem. 2005, 5, 603-624.
27. (b) Salerno, L.; Sorrenti, V.; Di Giacomo, C.; Romeo, G.; Siracusa, M. A. Progress in the Development of Selective Nitric Oxide Synthase (NOS) Inhibitors. Curr. Pharm. Des. 2002, 8, 177-200.
28. (c) Hobbs, A. J.; Higgs, A.; Moncada, S. Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 191-220.
29. (d) Marietta, M. A. Approaches Toward Selective Inhibition of Nitric Oxide Synthase. J. Med. Chem. 1994, 37, 1899-1907.
30. Ignarro, L. J.; Napoli, C.; Loscalzo, J. Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. Circ. Res. 2002, 90, 21-28.
31. Ji, H.; Li, H.; Flinspach, M.; Poulos, T. L.; Silverman, R. B. Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases: Implication for the Design of Isoform-Selective Inhibitors. J. Med. Chem. 2003, 46, 5700-5711.
32. (a) Silverman, R. B.; Huang, H.; Marietta, M. A.; Martásek, P. Selective Inhibition of Neuronal Nitric Oxide Synthase by Nω- Nitroarginine- and Phenylalanine-Containing Dipeptides and Dipeptide Esters. J. Med. Chem. 1997, 40, 2813-2817.
33. (b) Huang, H.; Martásek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. Nω-Nitroarginine-Containing Dipeptide Amides. Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. J. Med. Chem. 1999, 42, 3147-3153.
34. (a) Hah, J.; Roman, L. J.; Martásek, P.; Silverman, R. B. Reduced Amide Bond Peptidomimetics. (4S)-N-(4-Amino-5-[aminoalkyl]aminopentyl)- N′-nitroguanidines, Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase. J. Med. Chem. 2001, 44, 2667-2670.
35. (b) Gomez-Vidal, J. A.; Martásek, P.; Roman, L. J.; Silverman, R. B. Potent and Selective Conformationally Restricted Neuronal Nitric Oxide Synthase Inhibitors. J. Med. Chem. 2004, 47, 703-710.
36. (a) Hah, J.; Martásek, P.; Roman, L. J.; Silverman, R. B. Aromatic Reduced Amide Bond Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. J. Med. Chem. 2003, 46, 1661-1669.
37. (b) Mbadugha, B. N. A.; Seo, J.; Ji, H.; Martásek, P.; Roman, L. J.; Shea, T. M.; Li, H.; Poulos, T. L.; Silverman, R. B. Hydroxyl-terminated Peptidomimetic Inhibitors of Neuronal Nitric Oxide Synthase. Bioorg. Med. Chem. 2006, 14, 3681-3690.
38. Flinspach, M. L.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; Hah, J.; Gomez-Vidal, J. A.; Litzinger, E. A.; Silverman, R. B.; Poulos, T. L. Structural Basis for Dipeptide Amide Isoform-selective Inhibition of Neuronal Nitric Oxide Synthase. Nat. Struct. Mol. Biol. 2004, 11, 54-59.
39. Jensen, K. B.; Braxmeier, T. M.; Demarcus, M.; Frey, J. G.; Kilburn, J. D. Synthesis of Guanidinium-Derived Receptor Libraries and Screening for Selective Peptide Receptors in Water. Chem. Eur. J. 2002, 8, 1300-1309.
40. Zhao, J.; Pattaropong, V.; Jiang, Y.; Hu, L. Facile Synthesis and Cleavage of Imidazolidines in a Novel Protection Strategy for the Preparation of Peptides Containing a Reduced Amide Bioisostere. Tetrahedron Lett. 2003, 44, 229-232.
41. Dolbeare, K.; Pontoriero, G. F.; Gupta, S. K.; Mishra, R. K.; Johnson, R. L. iso-Lactam and Reduced Amide Analogues of the Peptidomimetic Dopamine Receptor Modulator 3(R)-[(2(S)-Pyrrolidinylcarbonyl)amino]-2-oxo- pyrrolidineacetamide. Bioorg. Med. Chem. 2003, 11, 4103-4112.
42. Voight, E. A.; Bodenstein, M. S.; Ikemoto, N.; Kress, M. H. Efficient Preparation of Chiral Diamines via Red-A1 reduction of N-Boc-protected Amino Acid-derived Secondary Amides. Tetrahedron Lett. 2006, 47, 1717-1720.
43. Roeske, R. W.; Weitl, F. L.; Prasad, K. U.; Thompson, R. M. Selective Reduction of the Amide Carbonyl Group in Dipeptides by Borane. J. Org. Chem. 1976, 41, 1260-1261.
44. (a) Hirel, C.; Vostrikova, K. E.; Pecaut, J.; Ovcharenko, V. I.; Rey, P. Nitronyl and Imino Nitroxides: Improvement of Ullman's Procedure and Report on a New Efficient Synthetic Route. Chem. Eur. J. 2001, 7, 2007-2014.
45. (b) Tepe, J. J.; Kosogof, C.; Williams, R. M. DNA Interstrand Cross-link Formation by Reductive Activation of Dehydropyrrolizidine Progenitors. Tetrahedron 2002, 58, 3553-3559.
46. Fields, J. D.; Kropp, P. J. Surface-Mediated Reactions. 9. Selective Oxidation of Primary and Secondary Amines to Hydroxylamines. J. Org. Chem. 2000, 65, 5937-5941.
47. Biloski, A. J.; Ganem, B. Improved Oxidation of Amines with Dibenzoyl Peroxide. Synthesis 1983, 7, 537-538.
48. (a) Vidal, J.; Damestoy, S.; Guy, L.; Hannachi, J.; Aubry, A.; Collet, A. N-Alkyloxycarbonyl-3-aryloxaziridines: Their Preparation, Structure, and Utilization as Electrophilic Amination Reagents. Chem. Eur. J. 1997, 3, 1691-1709.
49. (b) Guy, L.; Vidal, J.; Collet, A. Design and Synthesis of Hydrazinopeptides and Their Evaluation as Human Leukocyte Elastase Inhibitors. J. Med. Chem. 1998, 41, 4833-4843.
50. (a) Gómez-Vidal, J. A.; Silverman, R. B. Short, Highly Efficient Syntheses of Protected 3-Azido- and 4-Azidoproline and Their Precursors. Org. Lett. 2001, 3, 2481-2484.
51. (b) Gómez-Vidal, J. A.; Forrester, M. T.; Silverman, R. B. Mild and Selective Sodium Azide Mediated Cleavage of p-Nitrobenzoic Esters. Org. Lett. 2001, 3, 2477-2479.
52. Seo, J.; Silverman, R. B. Synthesis of Arginine-containing Hydroxamate Dipeptidomimetics. Tetrahedron Lett. 2006, 47, 4069-4073.
53. Fedorov, R.; Vasan, R.; Ghosh, D. K.; Schlichting, I. Structure of Nitric Oxide Synthase Isoforms Complexed with the Inhibitor AR-R17477 Suggest a Rational Basis for Specificity and Inhibitor Design. Proc. Natl Acad. Sci. U.S.A. 2004, 101, 5892-5897.
54. Garvey, E. P.; Oplinger, J. A.; Furfine, E. S.; Kiff, R. J.; Lasxlo, R.; Whittle, B. J. R.; Knowles, R. G. 1400W is a Slow, Right Binding, and Highly Selective Inhibitor of Inducible Nitric Oxide Synthase in vitro and in vivo. J. Biol. Chem. 1997, 272, 4959-4963.
55. Moriarty, N. W.; Karlstrom, G. Geometry Optimization of a Water Molecule in Water. A Combined Quantum Chemical and Statistical Mechanical Treatment. J. Chem. Phys. 1997, 106, 6470-6474.
56. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C. H.; Weber, P. C.; Jackson, D. A.; Sharpe, Erickson-Viitanen, T. R., S. Rational Design of Potent, Bioavailable, Non-peptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384.
57. Dunitz, J. D. The Entropic Cost of Bound Water in Crystals and Biomolecules. Science 1994, 264, p670.
58. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated Docking of Flexible Ligands: Applications of Autodock. J. Mol. Recognit. 1996, 9, 1-5.
59. Dupont, V.; Lecoq, A.; Mangeot, J.; Aubry, A.; Boussard, G.; Marraud, M. Conformational Perturbations Induced by N-Amination and N-Hydroxylation of Peptides. J. Am. Chem. Soc. 1993, 115, 8898-8906.
60. Jeffrey, G. A.; Saenger, W. Hydrogen Bonding in Biological Structures; Springer-Verlag: Berlin Heidelberg, 1991; p 51.
61. Massiah, M. A.; Viragh, C.; Reddy, P. M.; Kovach, I. M.; Johnson, J.; Rosenberry, T. L.; Mildvan, A. S. Short, Strong Hydrogen Bonds at the Active Site of Human Acetylcholinesterase: Proton NMR Studies. Biochemistry 2001, 40, 5682-5690.
62. Mikol, V.; Papageorgiou, C.; Borer, X. The Role of Water Molecules in the Structure-Based Design of (5-Hydroxynorvaline)-2-cyclosporin: Synthesis, Biological Activity, and Crystallographic Analysis with Cyclophilin A. J. Med. Chem. 1995, 38, 3361-3367.
63. Gangamani, B. P.; Kumar, V. A.; Ganesh, K. N. Synthesis of Nα-(purinyl/pyrimidinyl acetyl)-4-aminoproline Diastereomers with Potential Use in PNA Synthesis. Tetrahedron 1996, 52, 15017-15030.
64. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity-A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
65. Roman, L. J.; Sheta, E. A.; Martasek, P.; Gross, S. S.; Liu, Q.; Masters, B. S. S. High-Level Expression of Functional Rat Neuronal Nitric Oxide Synthase in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8428-8432.
66. Gerber, N. C.; Montelloano, P. R. Neuronal nitric oxide synthase. Expression in Escherichia coli, Irreversible Inhibition by Phenyldiazene, and Active Site Topology. J. Biol. Chem. 1995, 270, 17991-17996.
67. Martasek, P.; Liu, Q.; Roman, L. J.; Gross, S. S.; Sessa, W. C.; Masters, B. S. S. Characterization of Bovine Endothelial Nitric Oxide Synthase Expressed in Escherichia coli. Biochem. Biophys. Res. Commun. 1996, 219, 359-365.
68. Hevel, J. M.; Marietta, M. Nitric Oxide Synthase Assays. Methods Enzymol. 1994, 133, 250-258.
69. (a) Cheng, Y. C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
70. (b) Segal, I. H. Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems; John Wiley & Sons: New York, 1975; p 106.
71. (c) Burlingham, B. T.; Widlanski, T. S. An Intuitive Look at the Relationship of Ki and IC50: A More General Use for the Dixon Plot. J. Chem. Educ. 2003, 80, 214-218.
72. Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 1997, 276, 307-326.
73. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination. Acta Crystallogr. 1998, D54, 905-921.
74. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaarrd, M. Improved Methods for Building Models in Electron Density and the Location of Errors in These Models. Acta Crystallogr. 1991, A47, 110-119.